Search results for: 'drug tech eu'

The acute impact of climate change due to growing GHG emissions highlights the need for the technologies that can reduce said emissions while preparing the world s population for a scenario in which international targets are not achieved. While mitigation technologies seek to reduce or offset GHG emissions, adaptation technologies prepare communiti...

Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) ma...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...

With the healthcare industry moving toward patient convenience and comfort, pharmaceutical and medical device companies are continuously researching for the most effective, side effect free, convenient route of drug delivery. Transdermal drug delivery is a painless method of delivering drug formulation. Transdermal route of drug administration has ...

01 Mar 2024  |  North America  |  Market Research

Global Orphan Drug Growth Opportunities

Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

Infographics

×

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...

12 Aug 2020  |  North America  |  Market Research

New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019–2025

AI-powered Early Disease Diagnosis and Drug Repurposing will Create New Growth Opportunities

Infographics

×

Key Issues Addressed

Rare diseases have been an increasing area of focus as three waves have converged in recent years: genomic research and innovations becoming mainstream; the forthcoming regulatory policies and financial incentives put in place by the federal agencies; and the increasingly patient-centric and coordinated efforts of patient advocacy groups, caregive...

The climate emergency and the global economy's pivotal shift to net zero have prompted a need for transparent and accountable environmental, social, and governance (ESG) frameworks that can shape the transition of sustainability and the circular economy. The future of ESG, sustainability, and the circular economy will rely on delivering more with l...

Excipients are used to support the delivery of the APIs (active pharmaceutical ingredients) through oral dosage, parenteral, and transdermal medications. For oral dosages, the key delivery forms are tablets and capsules. This research service covers the North American oral solid drug dosage excipients market. Based on functionality, excipients are ...